[ Price : $8.95]
FDA releases a list of 13 potential safety signals identified in drugs between 7/2025 and 9/2025.[ Price : $8.95]
In a PDUFA 8 reauthorization subgroup discussion, FDA and industry representatives trade data and evaluations of first-cycle revie...[ Price : $8.95]
FDA seeks input on a new way to contract directly with venture capitalbacked innovators in an effort to possibly speed adoption of...[ Price : $8.95]
FDA posts an updated guidance outlining its processes for bioresearch monitoring inspections, which oversee the conduct, reporting...[ Price : $8.95]
FDA faces Increased scrutiny of its newly established Commissioners National Priority Review voucher program, which is intended to...[ Price : $8.95]
The New York Times reports that ongoing turmoil at FDA has increasingly placed commissioner Marty Makary under the microscope, rai...[ Price : $8.95]
FDA cites a GlaxoSmithKline biologicals manufacturing site in Hungary for significant lapses in deviation investigations and mater...[ Price : $8.95]
FDA posts two separate Form 483 inspection reports citing a range of quality and compliance deficiencies at Catalent Maryland, Inc...